Effects of ADMA upon Gene Expression: An Insight into the Pathophysiological Significance of Raised Plasma ADMA

Caroline L. Smith[*], Shelagh Anthony, Mike Hubank, James M. Leiper, Patrick Vallance

Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, United Kingdom

*To whom correspondence should be addressed. E-mail: c.l.smith@ucl.ac.uk

ABSTRACT

Background

Asymmetric dimethylarginine (ADMA) is a naturally occurring inhibitor of nitric oxide synthesis that accumulates in a wide range of diseases associated with endothelial dysfunction and enhanced atherosclerosis. Clinical studies implicate plasma ADMA as a major novel cardiovascular risk factor, but the mechanisms by which low concentrations of ADMA produce adverse effects on the cardiovascular system are unclear.

Methods and Findings

We treated human coronary artery endothelial cells with pathophysiological concentrations of ADMA and assessed the effects on gene expression using U133A GeneChips (Affymetrix). Changes in several genes, including bone morphogenetic protein 2 inducible kinase *(BMP2K),* SMA-related protein 5 *(Smad5),* bone morphogenetic protein receptor 1A, and protein arginine methyltransferase 3 *(PRMT3;* also known as *HRMT1L3),* were confirmed by Northern blotting, quantitative PCR, and in some instances Western blotting analysis to detect changes in protein expression. To determine whether these changes also occurred in vivo, tissue from gene deletion mice with raised ADMA levels was examined. More than 50 genes were significantly altered in endothelial cells after treatment with pathophysiological concentrations of ADMA (2 μM). We detected specific patterns of changes that identify pathways involved in processes relevant to cardiovascular risk and pulmonary hypertension. Changes in *BMP2K* and *PRMT3* were confirmed at mRNA and protein levels, in vitro and in vivo.

Conclusion

Pathophysiological concentrations of ADMA are sufficient to elicit significant changes in coronary artery endothelial cell gene expression. Changes in bone morphogenetic protein signalling, and in enzymes involved in arginine methylation, may be particularly relevant to understanding the pathophysiological significance of raised ADMA levels. This study identifies the mechanisms by which increased ADMA may contribute to common cardiovascular diseases and thereby indicates possible targets for therapies.

ADMA treatment of HCAEC

HCAEC were treated with 2 or 100 µM ADMA for 24 h and total RNA was harvested. Control cells were those not supplemented with ADMA. This was repeated on 3 separate occasions with cells less than P4, and total RNA extracted

Preparation of samples for U133A Genechips

cDNA was synthesised and subsequent biotinylated-cRNA synthesis was carried out according to Affymetrix standard protocols[12] (www.affymetrix.com). Labelled GeneChips were scanned using a confocal argon ion laser (Agilent Technologies). This yielded 9 chips: 3 untreated; 3 ADMA (2uM) and 3x ADMA (100µM).

Correction of signals on U133A Genechips and scaling. Filtering to remove unreliably detected genes

Data was scaled and transferred to Genespring 7.2 and the expression level of each gene was normalised against the median expression level for the entire gene set. Data was filtered to exclude genes if at this early stage of analysis the signal strength did not significantly exceed background values and if expression did not reach a threshold value for reliable detection (based on the relaxed Affymetrix MAS 5.0 probability of detection [P<0.1][34]) in each of the 3 separate studies. In order for genes to be assessed in the analysis they had to be present in all 3 replicates from the experiment. These criteria identified 10632 genes

T-tests to determine significantly changed genes

The mean of the median normalised values for expression of each individual gene were compared between the treated and untreated samples and the genes that changed by 2-fold, 1.7 fold and 1.5 fold was assessed. Statistical analysis of these changes was determined using the Welch T-test where p<0.05 was considered a statistically significant change.

Fold change	2-fold		1.7 fold		1.5 fold	
Number of genes changed	Total	P<0.05	Total	P<0.05	Total	P<0.05
Untreated v 2 µM	196	29	456	56	1926	223
Untreated v 100 µM	302	36	765	86	2609	310

Independent confirmation of gene changes

We selected 6 genes (BMP2K, PRMT3, RpS11, Calreticulin, SCAMP1 and RpL27A) and confirmed the expression of these genes, in independently treated HCAEC, by northern blotting, quantitative RT-PCR and western blotting as described in the manuscript

Identifying genes in related pathways

Following the confirmation of BMP2K as a significantly changed gene, the 765 genes changed greater than 1.7 fold (untreated v 100 µM) were examined to identify other genes which might be involved in the BMP signaling pathway. BMPR1A and Smad5 were identified from these lists and northern blotting was carried out to confirm that their expression did change significantly in HCAEC following exposure to ADMA.

Predicting global changes in gene expression in response to ADMA

In order to identify global changes in gene expression following ADMA treatment the genes changed greater than 1.7 fold (456 genes untreated v 2 µM and 765 genes untreated v 100 µM) were entered in to the NIH program DAVID-EASE[35] and biological processes effected by ADMA were predicted.

Figure 1. Flow Diagram Summarising the Methods Used in This Manuscript
DOI: 10.1371/journal.pmed.0020264.g001

Introduction

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of all nitric oxide synthase (NOS) isoforms [1]. It is synthesised by the action of protein arginine methyltransferases (PRMTs), and following proteolysis, free ADMA is released into the cell cytosol and thence into plasma. Circulating concentrations of ADMA are increased in patients with renal failure [1], pulmonary hypertension, heart failure, hypercholesterolemia or a wide range of other cardiovascular risk factors [2–6]. In patients with end-stage renal failure, the plasma levels of ADMA predict mortality and cardiovascular outcome [7], and in a cohort of otherwise healthy Finnish men, those with the highest levels of ADMA had an increased risk of acute coronary events [8]. Increased circulating ADMA in pregnant women predicts an increased risk of pre-eclampsia and intrauterine growth retardation [9].

Despite these clinical observations and the increasing excitement surrounding the use of ADMA as a risk marker for vascular disease [3,7], it is still not clear whether ADMA has a causal role in pathophysiology. It has been argued that the concentration of ADMA in plasma is too low to be an effective inhibitor of NOS, and that the usual concentrations of arginine in cells should overcome any inhibitory effects of ADMA on NOS [10]. In order to determine how ADMA might exert effects on endothelial cells and produce pathology, we assessed the effects of ADMA on gene expression in human coronary endothelial cells.

Methods

Cell Culture

Human coronary artery endothelial cells (HCAEC) were purchased from Promocell and grown according to the manufacturer's instructions. HCAEC in 75-cm^2 flasks at 70% confluency (passage 3 or 4) were treated for 24 h with complete media supplemented with asymmetric dimethylarginine ($N^G N^G$-dimethyl-L-arginine; ADMA; 0, 2, or 100 µM;

Table 1. Primer Sequences for Q-PCR and RT-PCR

Probe	3′ Oligo	5′ Oligo
BMP2K	TGTTGCTGCTGTGTTGCATGA	TATTGGGTCAGGGACCTCCTCA
SMAD5	CACCTCTCCACCAACATAGTAC	ATAATTCCCAGCCTATGGATAC
BMPR1A	TAGTTCGCTGAACCAATAAAGG	GTCAGAAAATGGAGTAACCTTA
PRMT3[a]	CTTCGCCCCAGCTTTA	TACGGGCATTATGGGAT
β-actin[a]	AAATCCTGAGTCAAGCCAAAAA	CCACGAAACTACCTTCAACTCC
mBMP2K	CTTCAGATCCCGGTGGATTA	ACACACCCGACCTCAACATT
mPRMT3	GACCCTGTTGTTGGCAATTCT	CTTCCTGTGGAAAAGGTGGA
mβ-actin	CATGATCTGGGTCATCTTTTCA	CATGATCTGGGTCATCTTTTCA

[a]Primers were designed for use on the LightCycler (Roche).
DOI: 10.1371/journal.pmed.0020264.t001

Merck Biosciences, United Kingdom). This was repeated on three separate occasions with different batches of cells. RNA from each study was used as described below for GeneChip (Affymetrix, Santa Clara, California, United States) analysis. Our strategy for the GeneChip and subsequent analysis is outlined in Figure 1.

GeneChip Experiments

ADMA-treated HCAEC from T75 flasks were harvested in 7.5 ml of TRIzol (Invitrogen, Carlsbad, California, United States), and total RNA was extracted; cDNA and subsequent cRNA synthesis were prepared as previously described [11]. The quality of the biotin-labelled cRNA transcripts was determined using a Bioanalyser 2100 (Agilent Technologies, Palo Alto, California, United States). Purified cRNA (15 μg) was fragmented and hybridised to human U133A GeneChips according to Affymetrix standard protocols (http://www.affymetrix.com). Labelled GeneChips were scanned, using a confocal argon ion laser (Agilent Technologies).

GeneChip Data Analysis

The U133A GeneChip contains oligonucleotides derived from approximately 22,000 human transcripts and includes control bacterial genes bioB, bioC, bioD, and cre. GeneChip data files scaled to 100 and normalised to the median prior to analysis with GeneSpring 7.2 software (Agilent; Figure 1). Genes were excluded if the signal strength did not significantly exceed background values and if expression did not reach a threshold value for reliable detection (based on the relaxed Affymetrix MAS 5.0 probability of detection ($p \leq 0.1$; [12]) in each of the three separate studies. Finally, genes were excluded if the level of expression did not vary by more than 1.7-fold between ADMA-treated (2 or 100 μM) compared with untreated control HCAEC. The remaining genes were subjected to nonparametric Welch t-tests and are reported with their respective fold changes and p-values. The data have been submitted in a MIAME-compliant format to ArrayExpress at EBI (http://www.ebi.ac.uk/arrayexpress/).

Determination of ADMA Levels

HCAEC cells were grown in 75-cm^2 flasks as described above for 24 h. Methylated arginines in the conditioned medium were quantitated by HPLC as previously described [1,13].

Cell Growth Assay

Cells were seeded into a 96-well microtitre plate at a density of 500 cells per well and grown in complete EC medium in the presence of 0, 2, or 100 μM ADMA. Cell growth was assayed (in triplicate) over a 4-d period using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, Wisconsin, United States).

Confirmation of Gene Changes

For genes of interest selected on the initial GeneChip analysis, further experiments were undertaken, with different batches of cells, to verify changes detected by global expression profiling and using different approaches to assess mRNA or protein.

RT-PCR

For RT-PCR cDNA was synthesised from the total RNA (approximately 1 μg) using Ready-To-Go You-Prime First-Strand Beads (Amersham Biosciences, Little Chalfont, United Kingdom) and supplemented with the 3′ gene-specific primers with β-actin as a control. RT-PCR used the primer sequences (Table 1) with β-actin as a control.

The PCR products were separated in 1% agarose gel, and the intensity of the bands was measured; each sample was corrected for β-actin. PCR products used for Northern blotting were excised and purified from agarose gel using Qiaex II (Qiagen, Valencia, California, United States).

Quantitative-PCR

Quantitative PCR (Q-PCR) was carried out using a LightCycler (Roche, Alameda, California, United States) and LightCycler software version 3, LightCycler run 4.24. All reagents required for PCR (excluding cDNA and primers) were included in the LightCycler FastStart DNA Master SYBR Green 1 kit (Roche). Reverse transcription was performed as described above for RT-PCR. The PCR cycle settings were 95 °C for 5 min, followed by 45 cycles of 95 °C for 5 s, 58 °C for 10 s (60 °C for β-actin), 72 °C for 40 s, and 77 °C (82 °C for β-actin), where fluorescence was measured at the end of each cycle and is gene-specific. Standard curves were constructed for PRMT3 as described by the manufacturer's instructions and compared to the reference gene β-actin.

Northern Blotting

HCAEC were grown to 70% confluency in 6-well plates and treated with 0, 2, and 100 μM ADMA, 100 μM L-N^5-(1-Iminoethyl)ornithine (L-NIO), or 100 μM symmetric dimethylarginine (SDMA) for 24 h; total RNA was extracted using

Table 2. Oligonucleotide Sequences for 5′-End-Labelling Northern Blotting Experiments

Gene	5′ Oligo
RpS11	AATAGCCTCCTTGGGTGTCTTGAA
Calreticulin	AGAGCAGATGAAATCTCAGGCCTGT
SCAMP1	AGACAGGTGCATTTAGGGATTCAAG
RpL27	GGTGCCATCATCAATGTTCTTCACG

DOI: 10.1371/journal.pmed.0020264.t002

A

B

Figure 2. Endothelial Gene Expression Changes in Response to ADMA

(A) Changes in HCAEC gene expression in response to ADMA. Hierarchical clustering of 131 genes significantly up- or downregulated ($p < 0.05$, Welch t-test) by greater than 1.7-fold on the U133A GeneChips in response to 2 μM ADMA (56 genes) or 100 μM ADMA (86 genes) compared with untreated cells with 11 genes changing with both concentrations of ADMA. Individual arrays are shown for each treatment group with blue representing low expression, and red high expression on the scale bar.

(B) Treatment of HCAEC with either 2 μM or 100 μM ADMA had no significant effect on cell viability; $n = 6$.

DOI: 10.1371/journal.pmed.0020264.g002

TRIzol, and RNA was separated by gel electrophoresis and blotted onto Hybond N$^+$ (Amersham Biosciences). The ribosomal protein S11 (*RpS11*), ribosomal protein L-27 (*RpL-27*), Calreticulin, and secretory carrier membrane protein 1 *(SCAMP1)* probes were generated by end-labelling 5′ oligonucleotides (Table 2) using T4 polynucleotide kinase.

The PCR products from RT-PCR reaction for *β-actin, Smad5,* bone morphogenetic protein receptor 1A *(BMPR1A)*, and murine *β*-actin *(mβ-actin)*; murine bone morphogenetic protein 2 inducible kinase *(mBMP2K),* and murine protein arginine methyltransferase 3 *(mPRMT3)* were purified and labelled with Redivue deoxycytidine 5′-[α-^{32}P]-triphosphate (Amersham Biosciences), using a random primed DNA labelling kit (Roche).

Western Blotting

HCAEC were treated with either 0, 2, or 100 μM ADMA for 24 h in 6-well plates and harvested in lysis buffer as described

previously [11], the protein concentrations of the lysates were determined by protein assay (Bio-Rad, Hercules, California, United States), and cell lysates were resolved by 12% SDS polyacryamide gel electrophoresis with equal amounts of protein loaded into each lane. Anti-PRMT3 (Upstate Biotechnology, Charlottesville, Virginia, United States) and Anti-BMP2K (Orbigen, San Diego, California, United States) were used with anti-rabbit secondary antibody coupled to horseradish peroxidase and detected with the ECL+ detection system (Amersham Pharmacia, Piscataway, New Jersey, United States). Densitometry of the bands was determined, and results are shown as the mean densitometry, where $n = 4$ with inset of a typical Western blot.

Pathway Mapping and Gene Ontology Analysis

In order to determine whether ADMA had affected expression of genes in pathways related to the genes identified on the initial analysis, lists of genes that were changed more than 1.7-fold compared to control (irrespective of p-value) were examined using Gene Ontology (Affymetrix) data mining for biological process (at level 3), and Expression Analysis Systematic Explorer (EASE) biological theme analysis were conducted online at http://david.niaid.nih.gov using DAVID [14]. DAVID-EASE [15] generates an EASE score predicting the likelihood of genes mapping to specific biological processes (determined by Gene Ontology consortium) from a given list of changed genes, therefore enabling global themes in gene expression following ADMA treatment to be identified [15].

Dimethylarginine Dimethylaminohydrolase 1 Gene Deletion Mice

ADMA is metabolised to citrulline and dimethylamine by the action of dimethylarginine dimethylaminohydrolase (DDAH). We have created knockout mice that lack DDAH1. DDAH1 heterozygous knockout mice (details to be published elsewhere) have approximately 2-fold higher plasma ADMA levels compared to wild-type litter-mates and thus provide an excellent model to test the effects of moderately raised ADMA levels in vivo. Northern blotting was carried out using RNA extracted from the brain, heart, and kidney of 12–14-wk-old DDAH1 heterozygous knockout and wild-type litter-mates with probes for *mBMP2K* and *mPRMT3*, and results are expressed relative to *mβ-actin*.

Statistical Analyses

Q-PCR, Northern blot, and Western blot densitometry data for the treated HCAEC was analysed by one-way analysis of variance (ANOVA) coupled to Bonferroni posttest, and the Bonferroni posttest p-values are reported. The Northern blots from the DDAH1 gene deletion mice were compared with unpaired t-test and the p-values are reported.

Results

Changes in HCAEC Gene Expression in Response to ADMA on U133A GeneChips

A total of 979 genes changed in expression between ADMA-treated and control cells. Following the Welch t-test with a cutoff of $p < 0.05$, 56 genes were identified as having shown a statistically significant change between the untreated and 2-μM ADMA-treated cells, and 86 genes changed between

Table 3. Genes That Changed by More Than 1.7-Fold in 2 μM ADMA Treated HCAEC Compared to Untreated

Affymetrix ID	Gene Title	Gene Symbol	Fold Change	p-Value
213350_at	[a]Ribosomal protein S11	RpS11	8.065	0.0334
222364_at	EST	—	5.780	0.0168
213642_at	[a]Ribosomal protein L27	RpL27	4.386	0.0481
216859_x_at	Golgi-specific brefeldin A resistance factor 1	GBF1	3.968	0.00706
212952_at	[a]Calreticulin	CALR	2.959	0.0472
204569_at	Intestinal cell (MAK-like) kinase	ICK	2.778	0.0491
203294_s_at	Lectin, mannose-binding, 1	LMAN1	2.740	0.0433
210407_at	Protein phosphatase 1A (formerly 2C), Magnesium-dependent, α-isoform	PPM1A	2.674	0.036
205636_at	SH3GL3 protein	SH3GL3	2.404	0.00324
38290_at	Regulator of G-protein signalling 14	RGS14	2.347	0.0235
208995_s_at	Peptidyl-prolyl isomerase G (cyclophilin G)	PPIG	2.315	0.0146
214716_at	[a]BMP2 inducible kinase	BMP2K	2.304	0.00128
213610_s_at	Hypothetical protein MGC2610	MGC2610	2.299	0.0435
212209_at	Thyroid hormone receptor associated protein 2	THRAP2	2.137	0.00562
214697_s_at	ROD1 regulator of differentiation 1 (Schizosaccharomyces pombe)	ROD1	2.132	0.02
213732_at	Transcription factor 3	TCF3	2.119	0.0462
220112_at	Hypothetical protein FLJ11795	FLJ11795	2.114	0.00623
219785_s_at	F-box protein 31	FBXO31	2.079	0.00429
206928_at	Zinc finger protein 124 (HZF-16)	ZNF124	2.045	0.0274
221903_s_at	Cylindromatosis (turban tumor syndrome)	CYLD	2.024	0.0221
204662_at	CP110 protein	CP110	2.012	0.0165
212746_s_at	KARP-1-binding protein	KAB	1.980	0.0379
217540_at	Transcribed locus, moderately similar to NP_055301.1 neuronal thread protein AD7c-NTP (Homo sapiens)	—	1.946	0.00294
202364_at	MAX interactor 1	MXI1	1.919	0.0268
204285_s_at	Phorbol-12-myristate-13-acetate-induced protein 1	PMAIP1	1.916	0.0443
204010_s_at	v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog	KRAS	1.905	0.046
202305_s_at	Fasciculation and elongation protein zeta 2 (zygin II)	FEZ2	1.862	0.028
201242_s_at	ATPase, Na+/K+ transporting, β-1 polypeptide	ATP1B1	1.845	0.0391
205416_s_at	Ataxin 3	ATXN3	1.845	0.00666
218096_at	1-Acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic acid acyltransferase, ε)	AGPAT5	1.838	0.00518
218930_s_at	Hypothetical protein FLJ11273	FLJ11273	1.828	0.0495
214700_x_at	RAP1 interacting factor homolog (yeast)	RIF1	1.818	0.00974
215203_at	Golgi autoantigen, golgin subfamily a, 4	GOLGA4	1.812	0.0128
202225_at	V-crk sarcoma virus CT10 oncogene homolog (avian)	CRK	1.805	0.0429
209318_x_at	Pleiomorphic adenoma gene-like 1	PLAGL1	1.805	0.0433
202906_s_at	Nijmegen breakage syndrome 1 (nibrin)	NBS1	1.773	0.0492
215948_x_at	Zinc finger protein 237	ZNF237	1.761	0.042
203202_at	HIV-1 rev binding protein 2	HRB2	1.718	0.0449
215412_x_at	Postmeiotic segregation increased 2-like 2	PMS2L2	1.706	0.0483
219021_at	Ring finger protein 121	RNF121	0.588	0.0311
208704_x_at	Amyloid β (A4) precursor-like protein 2	APLP2	0.582	0.0433
211590_x_at	Thromboxane A2 receptor	TBXA2R	0.579	0.0256
211385_x_at	Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2	SULT1A2	0.567	0.0237
217347_at	EST	—	0.563	0.0285
203873_at	Possible global transcription activator SNF2L1 (SWI/SNF related matrix associated actin-dependent regulator of chromatin subfamily A member 1).	SMARCA1	0.557	0.00757
222280_at	EST	—	0.551	0.0493
212699_at	Secretory carrier membrane protein 5	SCAMP5	0.547	0.0427
213484_at	Clone 23700 mRNA sequence	—	0.543	0.0464
209998_at	Phosphatidylinositol glycan, class O	PIGO	0.499	0.0408
216421_at	EST	—	0.481	0.0194
209093_s_at	Glucosidase, β; acid (includes glucosylceramidase)	GBA	0.468	0.0117
207740_s_at	Nucleoporin 62 kDa	NUP62	0.428	0.0404
217142_at	α subunit of the elongation factor-1 complex	EEF1A	0.416	0.0266
212822_at	HEG homolog	HEG	0.412	0.0221
205777_at	Dual specificity phosphatase 9	DUSP9	0.399	0.0055
208353_x_at	Ankyrin 1, erythrocytic	ANK1	0.205	0.0433

Fold changes and p-values of genes that changed by more than 1.7-fold in 2 μM ADMA treated HCAEC compared to untreated (p < 0.05 by Welch t-tests).
[a]Genes that were used for reanalysis in subsequent experiments.
DOI: 10.1371/journal.pmed.0020264.t003

the untreated and 100-μM ADMA greater than 1.7-fold; 11 genes showed statistically significant changes at both concentrations of ADMA compared to untreated cells (Figure 2A; Tables 3 and 4).

Effects of ADMA upon HCAEC Viability

Basal levels of ADMA and SDMA in HCAEC media were 0.17 ± 0.01 μM and 0.22 ± 0.02 μM, respectively, and arginine levels exceeded 300 μM. No changes were observed

Table 4. Genes that Changed by More than 1.7-Fold in 100 μM ADMA-Treated HCAEC Compared to Untreated

Affymetrix ID	Gene Title	Gene Symbol	Fold Change	p-Value
222364_at	EST	—	11.06	0.00597
216859_x_at	Golgi-specific brefeldin A resistance factor 1	GBF1	6.757	0.00045
204397_at	Echinoderm microtubule-associated protein-like	EMAP2	4.016	0.0201
212417_at	[a]Secretory carrier membrane protein 1	SCAMP1	3.165	0.0307
213734_at	Replication factor C (activator 1) 5, 36.5kDa	RFC5	2.740	0.0259
214716_at	[a]BMP2 inducible kinase	BMP2K	2.695	0.00049
214078_at	P21 (CDKN1A)-activated kinase 3	PAK3	2.500	0.0228
204142_at	Enolase superfamily member 1	ENOSF1	2.488	0.00326
221765_at	UDP-glucose ceramide glucosyltransferase	UGCG	2.392	0.00264
215218_s_at	Chromosome 19 open reading frame 14	C19orf14	2.336	0.0406
213732_at	Transcription factor 3	TCF3	2.315	0.0141
213610_s_at	Hypothetical protein MGC2610	MGC2610	2.309	0.0316
201424_s_at	Cullin 4A	CUL4A	2.278	0.0356
205636_at	SH3GL3 protein	SH3GL3	2.242	0.0395
217951_s_at	PHD finger protein 3	PHF3	2.183	0.0174
220112_at	Hypothetical protein FLJ11795	FLJ11795	2.128	0.00597
218297_at	Chromosome 10 open reading frame 97	C10orf97	2.020	0.0376
217540_at	Similar to NP_055301.1 neuronal thread protein AD7c-NTP	—	2.020	0.00341
222335_at	EST	—	2.016	0.00276
212936_at	Hypothetical protein DKFZp564D172	DKFZP564D172	1.949	0.0423
221649_s_at	Peter Pan homolog (Drosophila)	PPAN	1.898	0.0189
213320_at	[a]Protein arginine N-methyltransferase 3	PRMT3	1.883	0.0339
212209_at	Thyroid hormone receptor associated protein 2	THRAP2	1.883	0.0353
204237_at	GULP, engulfment adaptor PTB domain containing 1	GULP1	1.880	0.0299
205191_at	Retinitis pigmentosa 2 (X-linked recessive)	RP2	1.880	0.0324
202663_at	Wiskott-Aldrich syndrome protein interacting protein	WASPIP	1.869	0.023
212855_at	KIAA0276 protein	KIAA0276	1.862	0.0192
220255_at	Fanconi anemia, complementation group E	FANCE	1.821	0.0339
205296_at	Retinoblastoma-like 1 (p107)	RBL1	1.792	0.0458
206102_at	KIAA0186 gene product	KIAA0186	1.786	0.047
200605_s_at	Protein kinase, cAMP-dependent, regulatory, type I, α	PRKAR1A	1.767	0.0491
218256_s_at	Nucleoporin 54 kDa	NUP54	1.754	0.0223
221222_s_at	Hypothetical protein FLJ20519	FLJ20519	1.742	0.0163
221634_at	Similar to RPL23AP7 protein	MGC70863	1.736	0.0164
210148_at	Homeodomain interacting protein kinase 3	HIPK3	1.727	0.037
202419_at	Follicular lymphoma variant translocation 1	FVT1	1.721	0.0482
217542_at	Carboxypeptidase M	CPM	1.701	0.0122
209831_x_at	Deoxyribonuclease II, lysosomal	DNASE2	0.586	0.0186
200678_x_at	Granulin	GRN	0.579	0.0491
213829_x_at	Tumor necrosis factor receptor superfamily, member 6b, decoy	TNFRSF6B	0.577	0.0121
216041_x_at	Granulin	GRN	0.574	0.049
201434_at	Tetratricopeptide repeat domain 1	TTC1	0.573	0.0294
203778_at	Mannosidase, α A, lysosomal	MANBA	0.566	0.0395
207239_s_at	PCTAIRE protein kinase 1	PCTK1	0.565	0.0454
200913_at	Protein phosphatase 1G (formerly 2C),	PPM1G	0.564	0.0417
204473_s_at	Zinc finger protein 592	ZNF592	0.564	0.00276
218797_s_at	Sirtuin (silent mating type information regulation 2 homolog) 7 (Saccharomyces cerevisiae)	SIRT7	0.561	0.0219
200643_at	High-density lipoprotein binding protein (vigilin)	HDLBP	0.560	0.0398
211941_s_at	Prostatic binding protein	PBP	0.556	0.0387
207559_s_at	Zinc finger protein 261	ZNF261	0.552	0.0363
214035_x_at	LOC399491 protein	LOC399491	0.551	0.0113
216885_s_at	WD repeat domain 42A	WDR42A	0.551	0.0276
210589_s_at	Glucosidase, β; acid (includes glucosylceramidase)	GBA	0.550	0.014
203524_s_at	Mercaptopyruvate sulfurtransferase	MPST	0.550	0.0234
222217_s_at	Solute carrier family 27 (fatty acid transporter), member 3	SLC27A3	0.548	0.045
209140_x_at	Major histocompatibility complex, class I, B	HLA-B	0.544	0.0451
205851_at	Protein expressed in nonmetastatic cells 6, (nucleoside-diphosphate kinase)	NME6	0.543	0.00934
211471_s_at	RAB36, member RAS oncogene family	RAB36	0.541	0.0235
221757_at	HGFL gene	MGC17330	0.539	0.016
215533_s_at	Ubiquitination factor E4B (UFD2 homolog, yeast)	UBE4B	0.538	0.0229
215178_x_at	EST	—	0.534	0.0116
204248_at	Guanine nucleotide binding protein, α-11 (Gq class)	GNA11	0.532	0.00662
212744_at	Bardet-Biedl syndrome 4	BBS4	0.528	0.0119
208829_at	TAP binding protein (tapasin)	TAPBP	0.526	0.0292
209002_s_at	KIAA1536 protein	KIAA1536	0.522	0.0492
212040_at	Trans-Golgi network protein 2	TGOLN2	0.519	0.0129
216283_s_at	Poliovirus receptor	PVR	0.519	0.0351
219931_s_at	Kelch-like 12 (Drosophila)	KLHL12	0.510	0.0291

Table 4. Continued

Affymetrix ID	Gene Title	Gene Symbol	Fold Change	*p*-Value
202556_s_at	Microsphere protein 1	MCRS1	0.502	0.00625
218216_x_at	ADP-ribosylation-like factor 6 interacting protein 4	ARL6IP4	0.498	0.00504
211241_at	Lipocortin 2 pseudogene	LIP2	0.486	0.00553
202640_s_at	RAN binding protein 3	RANBP3	0.484	0.0406
210378_s_at	Sjogren's syndrome nuclear autoantigen 1	SSNA1	0.480	0.0381
209093_s_at	Glucosidase, β; acid (includes glucosylceramidase)	GBA	0.467	0.0216
211160_x_at	Actinin, α-1	ACTN1	0.463	0.018
217331_at	SCC-112 protein	SCC-112	0.463	0.0235
211911_x_at	Major histocompatibility complex, class I, B	HLA-B	0.444	0.0186
212822_at	HEG homolog	HEG	0.429	0.0275
208729_x_at	Major histocompatibility complex, class I, B	HLA-B	0.429	0.0301
210042_s_at	Cathepsin Z	CTSZ	0.401	0.0324
211230_s_at	Phosphoinositide-3-kinase, catalytic, δ polypeptide	PIK3CD	0.396	0.0428
203273_s_at	Tumor suppressor candidate 2	TUSC2	0.376	0.00316
218425_at	TRIAD3 protein	TRIAD3	0.360	0.0426
203143_s_at	KIAA0040 gene product	KIAA0040	0.354	0.0485
216180_s_at	Synaptojanin 2	SYNJ2	0.346	0.0329
206031_s_at	Ubiquitin-specific protease 5 (isopeptidase T)	USP5	0.209	0.0292

Fold changes and *p*-values of genes that changed by more than 1.7-fold in 100 μM ADMA-treated HCAEC compared to untreated (*p* < 0.05 by Welch *t*-tests).
[a]Genes that were used for reanalysis in subsequent experiments.
DOI: 10.1371/journal.pmed.0020264.t004

in HCAEC viability over 72 h in the presence of either 2 or 100 μM ADMA (Figure 2B).

Confirming Transcriptional Changes

To determine the reliability of changes identified by GeneChip analysis, four genes were selected from those that showed a statistically significant change in either the 2 or 100 μM sample compared to control (Figure 3A). These were *SCAMP1, Calreticulin, (RpL27)* and *RpS11*. In studies on a different batch of HCAEC, Northern blotting confirmed that expression of these genes changed in response to ADMA (Figure 3B).

In order to elucidate the mechanism of ADMA action, HCAEC were also treated with the potent NOS inhibitor L-NIO and SDMA, which is not a NOS inhibitor or DDAH substrate, but is a naturally occurring methylarginine that competes with arginine for the cationic amino acid transporter [10,16]. Interestingly neither SDMA nor L-NIO elicited significant changes in the expression of *RpS11, RpL27, SCAMP1,* or *Calreticulin* (Figure 3B).

Genes of Specific Interest Identified by GeneChip

Protein arginine methyltransferase. *PRMT3* was selected as a gene of interest, because of its involvement in ADMA synthesis [17]. It changed 1.8-fold on the GeneChip untreated versus 100 μM groups (*p* = 0.0339; Figure 4A). In a separate series of follow-up studies, HCAEC were treated with ADMA, and *PRMT3* gene expression was determined by Q-PCR. *PRMT3* mRNA levels increased following either low- or high-dose ADMA treatment (Figure 4B untreated versus 2 μM, *p* < 0.05; and untreated versus 100 μM, *p* < 0.01, *n* = 6). PRMT3 protein expression also increased in response to ADMA treatment (Figure 4C; untreated versus 2 μM; and untreated versus 100 μM, *p* < 0.05, *n* = 4). When HCAEC were treated for 24 h with 2 μM SDMA or L-NIO, neither treatment significantly affected *PRMT3* expression, whereas 100 μM SDMA or L-NIO caused a small increase in *PRMT3* expression (Figure 4B; *n* = 6).

Bone morphogenetic protein 2 inducible kinase. We identified that bone morphogenetic protein 2 inducible kinase *(BMP2K)* changed on the GeneChip in response to ADMA (2 μM and 100 μM ADMA increased expression by 2.304-fold [*p* = 0.00128] and 2.695-fold [*p* < 0.001], respectively; Figure 5A). In a separate series of experiments on a different batch of HCAEC this increase in *BMP2K* expression was confirmed by RT-PCR (data not shown). Western blotting also revealed that BMP2K protein levels were increased in response to ADMA (Figure 5B); densitometry of these blots indicated that there was a significant increase (untreated versus 2 μM, *p* < 0.05; and untreated versus 100 μM, *p* < 0.01, *n* = 4).

Identification of Genes Involved in Bone Morphogenetic Protein Signalling

Having confirmed changes in *BMP2K* expression, the total list of 765 genes that changed greater than 1.7-fold in response to 100 μM ADMA, was reexamined to identify additional genes in the bone morphogenetic protein (BMP) signalling pathway affected by ADMA. This analysis identified *Smad5* and *BMPR1A* (Figures 6 and 7). In a separate set of studies Northern blotting confirmed that mRNA was increased in HCAEC after 24 h by either 2 or 100 μM ADMA for *Smad5* and *BMPR1A* (*Smad5* untreated versus 2 μM and untreated versus 100 μM; *p* < 0.05, *n* = 4; Figure 6A; and *BMPR1A* untreated versus 2 μM, *p* < 0.05 and untreated versus 100 μM; *p* < 0.01, *n* = 4; Figure 6B).

Identification of Global Changes in Gene Expression

All genes that changed by more than 1.7-fold (irrespective of *p*-value) were entered into DAVID-EASE. EASE probability scores were generated based upon the number of genes for each biological process altered in response to ADMA (Tables 5 and 6), where these biological processes were defined by

Figure 3. Confirmation of Gene Expression Changed by GeneChip Analysis

(A) *SCAMP1; Calreticulin,* ribosomal protein L-27 *(RpL27),* and *RpS11* signal-to-noise ratios derived from U133A GeneChip analysis where $n = 3$ (untreated versus 100 µM: *SCAMP1* changed 3.16-fold, $p = 0.031$; and untreated versus 2 µM: *Calreticulin* changed 2.96-fold, $p = 0.047$; *RpS11*, 8.065-fold, $p = 0.033$; *RpL27*, 4.39-fold, $p = 0.048$).

(B) *SCAMP1; Calreticulin, RpL27*, and *RpS11* mRNA levels are elevated by ADMA (2 and 100 µM; *$p < 0.05$ and **$p < 0.01$). SDMA (100 µM) and L-NIO (100 µM) did not elicit changes in gene expression as shown by Northern blotting, where mRNA was corrected for differences in β-actin mRNA expression.

DOI: 10.1371/journal.pmed.0020264.g003

enriched Gene Ontology categories. These gene lists indicated that ADMA affects genes involved in metabolism, RNA splicing, transcription, and cell cycle regulation.

Gene Deletion Mice

To examine whether the effects observed in the cell culture model were relevant to the in vivo situation, we determined the expression level of certain genes in DDAH heterozygous knockout mice that have 2-fold elevation in plasma ADMA levels. Total RNA from DDAH1 heterozygous knockout was probed for *mBMP2K* and *mPRMT3* by Northern blotting and corrected for *mβ-actin* expression (Figure 8). Levels of *mBMP2K* for brain, heart, and kidney, respectively, were 42 ± 13.8% ($p = 0.047$), 33.3 ± 18.6% ($p = 0.038$), 74.0 ± 21.4% ($p = 0.007$), higher in DDAH1 heterozygous mice ($n = 9$) compared with wild-type litter-mates ($n = 5$). A similar trend was seen for the expression of *mPRMT3* (data not shown).

Discussion

ADMA is an endogenous inhibitor of NOSs [1] and there is an association between increased plasma levels of ADMA and renal disease [1], pulmonary hypertension [5], preeclampsia [9], and the progression of atherosclerosis [18,19]. Whilst the concentration of ADMA in plasma of healthy adults varies between 0.4 and 1 µM, it may increase to 1.45–4.0 µM with certain diseases, and this increase is thought to be causally involved in pathophysiology [1,6,7,9,20]. In the present study we detected substantial changes in gene expression in HCAEC after 24 h of exposure to concentrations of ADMA similar to those reported in pathophysiological states. Furthermore, we identified specific pathways of gene activation that give insight into the mechanisms by which ADMA may contribute to disease. Surprisingly, some of these changes appear to be independent of blockade of the L-arginine:nitric oxide (NO) pathway.

Figure 4. ADMA Alters PRMT3 Gene Expression and Protein Levels

(A) *PRMT3* levels are changed by ADMA on U133A GeneChips where $n = 3$ (untreated versus 100 μM: 1.88-fold increase, $p = 0.034$).

(B) *PRMT3* mRNA is changed in HCAEC following 24-h exposure to ADMA (2 and 100 μM) but not SDMA (100 μM) or L-NIO (100 μM), measured by Q-PCR (*$p < 0.05$ and **$p < 0.01$, where $n = 8$).

(C) PRMT3 protein levels are increased in HCAEC following 24-h treatment with ADMA (2 and 100 μM) as determined by Western blotting, using a commercially available PRMT3 antibody (Upstate Biotechnology), where equal amounts of protein were loaded in each lane. Densitometry of the PRMT3 was carried for each of the blots from four separate experiments. ADMA (2 and 100 μM) treatment for 24 h significantly increased the levels of PRMT3 (*$p < 0.05$). The inset blot is a representative from four separate experiments.

DOI: 10.1371/journal.pmed.0020264.g004

Figure 5. ADMA Alters BMP2K Gene Expression and Protein Levels

(A) *BMP2K* is increased more than 2-fold in HCAEC following 24-h ADMA treatment (2 μM and 100 μM ADMA increased expression by 2.304-fold [$p = 0.00128$] and 2.695-fold [$p < 0.001$] respectively).

(B) BMP2K protein levels are increased in HCAEC following 24-h treatment with ADMA (2 and 100 μM) as determined by Western blotting, using a commercially available BMP2K antibody (Orbigen). Densitometry of the BMP2K band was carried for each of the blots from four separate experiments (untreated versus 2 μM: $p < 0.05$; and untreated versus 100 μM: $p < 0.01$, $n = 4$). The inset blot is representative of four separate experiments, where equal amounts of protein were loaded in each lane.

DOI: 10.1371/journal.pmed.0020264.g005

Low Concentrations of ADMA Alter Gene Expression

Acute administration of ADMA to healthy individuals elicits a transient fall in heart rate and cardiac output and increases blood pressure [2], but little is known of the potential longer-term effects of raised ADMA. Zoccali et al. reported that a 1-μM increment in ADMA above the upper limits for healthy individuals was associated with increased risk of cardiovascular mortality [7], and levels around 2 μM seem to be associated with a number of diverse cardiovascular pathologies [3,8]. In the current study, HCAEC were treated with 2 or 100 μM ADMA. We repeated GeneChip analysis in three separate studies and observed reproducible changes in the expression of a subset of genes in response to low- and high-dose ADMA. Because there is always a possibility of false positives being identified on arrays, we tested the reproducibility of the GeneChip approach by selecting four genes significantly upregulated by ADMA treatment. In a separate series of studies we confirmed an increase in mRNA levels by Northern blotting at both concentrations of ADMA. Thus it is clear that pathophysiological concentrations of ADMA (2 μM) affect endothelial cell gene expression even in the presence of very high arginine concentrations (>300 μM). Endogenous ADMA is metabolised by DDAH, and DDAH activity is the major determinant of plasma ADMA concentrations [2]. To determine whether the effects we saw in vitro would be reproduced in vivo we examined DDAH1 knockout mice. At least one of the gene changes we saw in vitro also occurs in vivo since DDAH1 heterozygous knockout mice have increased concentrations of ADMA in plasma and showed upregulation of *BMP2K* in several tissues.

ADMA inhibits NOSs with an IC_{50} of about 5 μM, the precise potency depending on the prevailing concentration

Figure 6. Genes Involved in BMP Signalling are Altered by ADMA

Smad5 (A) and BMPR1A (B) are elevated in HCAEC following 24-h treatment with ADMA (2 and 100 µM), as shown by Northern blotting where mRNA was corrected for differences in β-actin mRNA expression ($*p < 0.05$; $** p < 0.01$, where $n = 4$).
DOI: 10.1371/journal.pmed.0020264.g006

Figure 7. Involvement of ADMA-Affected Genes in the BMP Signalling Pathway

Squares in yellow show genes that increased significantly on the GeneChip, whilst squares in blue show genes decreased by ADMA compared to untreated HCAEC, and "?" represents an unknown mechanism of action.
DOI: 10.1371/journal.pmed.0020264.g007

of arginine [21]. It is known that adding endogenous NO to endothelial cells alters gene expression [22,23] and that inhibitors of endogenous NO generation can alter expression of specific genes, at least under conditions of endothelial cell activation with cytokines. To determine whether the effects we observed could be accounted for by inhibition of NOS, we treated cells with a highly potent NOS inhibitor (L-NIO) and with SDMA, an endogenous dimethylarginine that has no effect on NOS but which can block arginine transport [10,16]. Neither SDMA nor L-NIO replicated the effects of ADMA on gene expression. We have not undertaken a full GeneChip analysis of responses to L-NIO, so we do not know how much overlap there would be between the effects of L-NIO and ADMA, but of those genes examined we saw a discordance between responses to the two inhibitors. This raises the intriguing possibility that some of the actions of ADMA may be independent of effects of NO, possibly due to other actions such as the ability of ADMA to increase superoxide generation [24,25]. Other authors have reported differences in efficacy of ADMA in cell culture systems compared to other NOS inhibitors that have more potent effects on isolated NOS [26], and further studies will be required to identify to what extent NO-independent effects contribute to the overall action of ADMA. Interestingly, a NOS-independent effect of ADMA on angiotensin-converting enzyme has recently been suggested [25]. NOS-independent effects of ADMA may explain why, in some situations where ADMA concentrations are raised, L-arginine does not restore normal endothelial function [27] and why ADMA can exert effects, even in the presence of high endogenous arginine concentrations.

Patterns of Gene Change

Mapping genes changed by ADMA to identify global changes in biological processes [15], indicated that ADMA treatment may have significant effects on genes involved in cell cycle regulation, cell proliferation, DNA repair, transcriptional regulation, and metabolism. The full biological significance of the range of genes affected is not yet known, but our data demonstrate the potential for elevated ADMA to affect endothelial (and likely other cellular) function in disease. In the present study, we focussed on two pathways of potential importance—BMP pathways and PRMTs.

BMP Pathways and ADMA

Analysis of the U133A GeneChips revealed that BMP2K was induced more than 2-fold in response to either 2 or 100 µM ADMA. The increase in gene expression was mirrored by an increase in BMP2K protein, and the effect was also seen in our high-ADMA mouse model. By relaxing parameters (to exclude false negatives) a search for other genes involved in BMP signalling revealed that Smad5 and BMPR1A were also amongst the transcripts increased by GeneChip analysis, and these changes were confirmed by Northern blotting. The finding of changes in the BMP signalling pathway is important since the ADMA/DDAH pathway seems to be involved in animal models of pulmonary hypertension [28,29], and mutations in the BMP receptor 2 (BMPR2) are associated with familial pulmonary hypertension in humans [30].

The changes in BMP pathways may also be important in understanding some of the effects of renal failure. ADMA accumulates in renal failure and fulfils many of the criteria of a uraemic toxin [1,18]. In addition to effects on cardiovas-

Table 5. Identification of Global Changes in Gene Expression in HCAEC Following Treatment with 2 µM ADMA

Biological Process	Number of Genes Mapped to Process	EASE Score
Metabolism	161	0.0252
Nucleobase, nucleoside, nucleotide, and nucleic acid metabolism	77	0.0305
RNA splicing	8	0.0324
Antigen presentation, endogenous antigen	3	0.0337
Antigen processing, endogenous antigen via MHC class I	3	0.0337
Chromatin modification	6	0.0371
Antigen processing	4	0.0389
Regulation of transcription	50	0.0398
Protein metabolism	67	0.0407
Antigen presentation	4	0.0434
Cell organization and biogenesis	22	0.0441
Cell growth and/or maintenance	96	0.0462
Double-strand break repair	3	0.0493
Transcription	52	0.0506

Genes that changed by more than 1.7-fold in 2 µM treated compared to untreated HCAEC (465) were analysed by DAVID-EASE [15] software (National Institutes of Health) to determine biological processes, based on gene ontology, likely to have been affected by ADMA treatment.
MHC, major histocompatibility complex.
DOI: 10.1371/journal.pmed.0020264.t005

Table 6. Identification of Global Changes in Gene Expression in HCAEC Following Treatment with 100 µM ADMA

Biological Process	Number of Genes Mapped to Process	EASE Score
Cell growth and/or maintenance	183	0.0000126
Cytoplasm organization and biogenesis	29	0.000463
Cellular physiological process	199	0.000579
Antigen processing, endogenous antigen via MHC class I	5	0.00103
Organelle organization and biogenesis	25	0.00141
Antigen processing	7	0.00142
Intracellular transport	35	0.0029
Cytoskeleton organization and biogenesis	20	0.00393
Cell cycle	45	0.00939
Antigen presentation	6	0.00996
Intracellular protein transport	27	0.00997
Antigen presentation, endogenous antigen	4	0.0118
Cell proliferation	62	0.0138
Negative regulation of cell cycle	10	0.0141
Transport	86	0.0142
Positive regulation of cell proliferation	12	0.0157
Protein transport	27	0.0164
Regulation of cell cycle	28	0.0203
Cell organization and biogenesis	35	0.0272
Regulation of cell proliferation	20	0.0305
Pyrimidine nucleotide biosynthesis	4	0.0414
Vesicle-mediated transport	18	0.0487

Genes that changed by more than 1.7-fold in 100 µM treated compared to untreated HCAEC (765) were analysed by DAVID-EASE [15] software (National Institutes of Health) to determine biological processes likely to have been affected by ADMA treatment.
MHC, major histocompatibility complex.
DOI: 10.1371/journal.pmed.0020264.t006

cular risk, ADMA may contribute to renal osteodystrophy, a process in which BMPs have been implicated [31]. Indeed an earlier study that showed that ADMA reduces osteoblast differentiation and decreases osteocalcin expression [32]. The present study confirms osteocalcin as a gene downregulated by ADMA, and since activation of *BMP2K* attenuates osteocalcin expression and reduces osteoblast differentiation [33], it is possible that the effects of ADMA on osteocalcin may be secondary to induction of *BMP2K* (Figure 7). Whatever the mechanisms, identification of a link between ADMA and BMP pathways may be relevant to the increased vascular calcification seen in renal disease [31].

ADMA and Arginine Methylation

We observed that *PRMT3* gene expression was elevated following exposure to ADMA; this was confirmed by Q-PCR, and PRMT3 protein expression also increased. This is the first report that ADMA may alter the expression of enzymes involved in its own synthesis. There are presently five known PRMTs that asymmetrically methylate arginine residues and two (PRMT5 and PRMT7) that symmetrically methylate arginine residues. PRMT3 has a wide tissue distribution, is expressed in highly vascular tissues, including heart and lung [17], and expression may be increased by oxidised-LDL [34]. Our observations indicate that ADMA can induce a similar increase in PRMT3 expression.

The roles of methylation of arginine residues in proteins are not yet well defined, but studies of PRMT3 in fission yeast have shown that it associates with proteins involved in the translational machinery and that the S2 ribosomal protein, a component of the yeast 40S ribosome, is a specific substrate for PRMT3 [35]. PRMT3 is the only PRMT known to interact with the translational machinery, and it is interesting that we

have found several genes, including ribosomal proteins *RpS11* and *RpL27*, involved in translational control, that were also altered in response to ADMA treatment. Amongst the genes changed greater than 1.7-fold in response to ADMA was methionine adenosyltransferase II α, which catalyses the production of S-adenosylmethionine, the methyl donor for the PRMT reaction [36]. The role of ADMA in regulating arginine methylation in protein deserves further study.

Summary

Increased circulating concentrations of ADMA have been reported in cardiovascular and other disorders, and intracellular concentrations may vary independently of circulating levels. In the present study we have demonstrated that relatively small changes in the concentration of ADMA affect gene expression in endothelial cells. Identification of pathways regulated by ADMA may aid our understanding of how ADMA contributes to a wide range of pathologies. Two pathways of specific interest have been identified—BMP signalling and enzymes involved in arginine methylation. The effects on BMP signalling may be particularly important in renal disease and in the link between raised ADMA and pulmonary hypertension.

Supporting Information

Accession Numbers
The microarray data have been loaded into the EBI MIAMExpress database (http://www.ebi.ac.uk/miamexpress/) and have been assigned the accession number E-MEXP-377.

Figure 8. BMP2K Is Increased in DDAH1 Gene Deletion Mice

Expression of *BMP2K* mRNA from brain, heart, and kidney is increased in 12-wk DDAH1 heterozygous knockout mice compared to wild-type littermates ($p = 0.0473$, $p = 0.0379$, and $p = 0.0070$, respectively); mRNA was corrected for differences in *β-actin* mRNA expression, where $n = 5$ wild type, and $n = 9$ DDAH heterozygous.

DOI: 10.1371/journal.pmed.0020264.g008

Acknowledgments

References

1. Vallance P, Leone A, Calver A, Collier J, Moncada S (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572–575.
2. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, et al. (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23: 1455–1459.
3. Cooke JP (2004) Asymmetrical dimethylarginine: The Uber marker? Circulation 109: 1813–1818.
4. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, et al. (1998) Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 62: 2425–2430.
5. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE (2001) Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 37: 489–492.
6. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, et al. (1998) Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 98: 1842–1847.
7. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, et al. (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358: 2113–2117.
8. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, et al. (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358: 2127–2128.
9. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, et al. (2003) Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 361: 1511–1517.
10. Tsikas D, Boger RH, Sandmann J, Bode-Boger SM, Frolich JC (2000) Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett 478: 1–3.
11. Chambers RC, Leoni P, Kaminski N, Laurent GJ, Heller RA (2003) Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol 162: 533–546.
12. Seo J, Bakay M, Chen YW, Hilmer S, Shneiderman B, et al. (2004) Interactively optimizing signal-to-noise ratios in expression profiling: Project-specific algorithm selection and detection *p*-value weighting in Affymetrix microarrays. Bioinformatics 20: 2534–2544.
13. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA (2002) Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303: 131–137.
14. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
15. Hosack DA, Glynn Dennis G, Sherman BT, Lane BC, Lempicki RA (2003) Identifying biological themes within lists of genes with EASE. Genome Biol 4: R70.
16. Closs EI, Basha FZ, Habermeier A, Forstermann U (1997) Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1: 65–73.
17. Tang J, Gary JD, Clarke S, Herschman HR (1998) PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation. J Biol Chem 273: 16935–16945.
18. Kielstein JT, Bode-Boger SM, Frolich JC, Haller H, Boger RH (2001) Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int Suppl 78: S9–S13.
19. Zoccali C (2002) Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease. Blood Purif 20: 469–472.
20. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, et al. (2002) Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287: 1420–1426.
21. MacAllister RJ, Whitley GS, Vallance P (1994) Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 45: 737–742.
22. Faruqi TR, Erzurum SC, Kaneko FT, DiCorleto PE (1997) Role of nitric oxide in poly(I-C)-induced endothelial cell expression of leukocyte adhesion molecules. Am J Physiol 273: (5 Pt 2): H2490–H2497.
23. Hemish J, Nakaya N, Mittal V, Enikolopov G (2003) Nitric oxide activates diverse signaling pathways to regulate gene expression. J Biol Chem 278: 42321–42329.
24. Cardounel AJ, Xia Y, Zweier JL (2005) Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric oxide synthase: Differences in the effects of monomethyl and dimethyl arginines in the presence and absence of tetrahydrobiopterin. J Biol Chem 280: 7540–7549.
25. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, et al. (2004) Asymmetric dimethylarginine causes arteriosclerotic lesions in endothelial nitric oxide synthase-deficient mice: Involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 24: 1682–1688.
26. Smirnova IV, Kajstura M, Sawamura T, Goligorsky MS (2004) Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: Role in foam cell formation. Am J Physiol Heart Circ Physiol 287: H782–H790.
27. Cross JM, Donald AE, Kharbanda R, Deanfield JE, Woolfson RG, et al. (2001) Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure. Kidney Int 60: 2318–2323.
28. Arrigoni FI, Vallance P, Haworth SG, Leiper JM (2003) Metabolism of

asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 107: 1195–1201.

29. Millatt LJ, Whitley GS, Li D, Leiper JM, Siragy HM, et al. (2003) Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 108: 1493–1498.

30. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, et al. (2000) Familial primary pulmonary hypertension (gene *PPH1*) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67: 737–744.

31. Hruska KA, Saab G, Chaudhary LR, Quinn CO, Lund RJ, et al. (2004) Kidney-bone, bone-kidney, and cell–cell communications in renal osteodystrophy. Semin Nephrol 24: 25–38.

32. Xiao ZS, Quarles LD, Chen QQ, Yu YH, Qu XP, et al. (2001) Effect of asymmetric dimethylarginine on osteoblastic differentiation. Kidney Int 60: 1699–1704.

33. Kearns AE, Donohue MM, Sanyal B, Demay MB (2001) Cloning and characterization of a novel protein kinase that impairs osteoblast differentiation in vitro. J Biol Chem. 276: 42213–42218.

34. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, et al. (2000) LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87: 99–105.

35. Bachand F, Silver PA (2004) PRMT3 is a ribosomal protein methyltransferase that affects the cellular levels of ribosomal subunits. EMBO J 23: 2641–2650.

36. Casellas P, Jeanteur P (1978) Protein methylation in animal cells. II. Inhibition of S-adenosyl-L-methionine:protein(arginine) N-methyltransferase by analogs of S-adenosyl-L-homocysteine. Biochim Biophys Acta 519: 255–268.

Patient Summary

Background Diseases of the circulation system are common and cause many deaths. Medical conditions associated with damage to the blood vessels include heart failure, high blood pressure, stroke, and kidney failure. The lining of the blood vessels plays an active role in maintaining their health. A substance called asymmetric dimethylarginine (ADMA) is found naturally in the vessel lining, both in healthy people and in people with vascular disease, but in the latter it is present at higher levels. Thus raised ADMA may be a marker of vascular disease. This means it could be used to help identify people with a circulation problem. However, it has not been clear whether ADMA actually causes any damage, i.e., whether it is more than just a marker.

What Did the Researchers Do and Find? The researchers are trying to find out whether elevated ADMA levels can cause vascular disease. In this study, they treated cells from blood vessel linings with levels of ADMA equal to those found in people with vascular disease and measured how gene activity changed in response. They found that a number of genes were more active when the cells were exposed to the elevated ADMA levels. Some of these were interesting because other studies suggest that they might be involved in lung, heart, and kidney disease.

What Do the Results Mean for Patients? This area of research is still at an exploratory stage. Additional studies need to examine which function (if any) the genes that respond to elevated ADMA levels play in vascular disease. If they do play active roles, drugs that inhibit them might help to prevent or treat vascular disease.

Where Can I Get More Information? For general information on cardiovascular disease see information provided by the following organisations.

The British Heart Foundation:
http://www.bhf.org.uk/hearthealth/index_home.asp?SecID=1
The American Academy of Family Physicians:
http://familydoctor.org/292.xml
The National Heart, Lung, and Blood Institute:
http://www.nhlbi.nih.gov/health/public/heart/index.htm
New York Online Access to Health:
http://www.noah-health.org/en/blood/vascular/index.html
University College London:
http://www.ucl.ac.uk/medicine/clinical-pharmaco/research